A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
This study is an open-label, multi-centre, single-arm, phase I clinical study, to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510 (an anti-PD-L1/VEGF bispecific antibody fusion protein) + IMM27M (a humanized Fc-engineered anti-CTLA-4 antibody) combination therapy
| Condition(s) | Advanced Solid Tumors, HCC |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | This study is an open-label, multi-centre, single-arm, phase I clinical study, to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510 (an anti-PD-L1/VEGF bispecific antibody fusion protein) + IMM27M (a humanized Fc-engineered anti-CTLA-4 antibody) combination therapy in patients with advanced solid tumors. |
| Who can participate | Inclusion Criteria: 1. The patient can understand the procedures and methods of this clinical trial. After giving full informed consent, the patient voluntarily participates in it and signs the informed consent form. 2. Aged between 18 and 75 years old (including both ends), regardless of gender. 3. Clinical diagnosis: Dose escalation phase: Patients with advanced malignant solid tumors confirmed by histology or cytology, who have failed previous standard treatments, have no standard treatment regimens or are not suitable for standard treatment at present, including but not limited to hepatocellular carcinoma, triple-negative breast cancer, soft tissue sarcoma, non-small cell lung cancer, epithelial ovarian cancer, small cell lung cancer, malignant melanoma, colorectal cancer, ovarian canc |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
| Locations | Shanghai, Shanghai Municipality, China |
| Start date | 2024-07-23 |
| NCT ID | NCT06764836 |
| Official listing | https://clinicaltrials.gov/study/NCT06764836 |